A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Etrasimod (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms ELEVATE 12; ELEVATE UC 12
- Sponsors Arena Pharmaceuticals
Most Recent Events
- 10 Mar 2024 According to Everest Medicines media release, data for maintenance period is expected for readout in 2H 2024.
- 19 Feb 2024 According to a Pfizer media release, the marketing authorization for VELSIPITY is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway. Regulatory applications for VELSIPITY in UC have been submitted to additional countries around the world for review.
- 19 Feb 2024 According to a Pfizer media release, based on results from the ELEVATE UC 52 and ELEVATE UC 12, the European Commission has granted marketing authorization for VELSIPITY in the EU to treat patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.